Christian Poehlein

Diagnosis and management of neuroendocrine prostate cancer

The Prostate 2024cited by 37position: middledoi

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Journal of Clinical Oncology 2023cited by 90position: middledoi

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

European Urology 2022cited by 66position: middledoi

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26]

European Urology 2022cited by 6position: middledoi

Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.

Journal of Clinical Oncology 2021cited by 21position: middledoi

612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

Annals of Oncology 2021cited by 8position: middledoi

KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology 2020cited by 39position: middledoi

217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study

Annals of Oncology 2020cited by 5position: middledoi

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Journal of Clinical Oncology 2019cited by 699position: middledoi

Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology 2019cited by 52position: middledoi

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

Journal of Clinical Oncology 2019cited by 7position: middledoi

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

New England Journal of Medicine 2017cited by 3,373position: middledoi

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Cancer Immunology Immunotherapy 2012cited by 262position: middledoi

Recent publications

Grants

Frequent collaborators